Latest Hotspot

REGN7075 Bispecific Antibody Shows Anti-Tumor Effects with Libtayo, Findings at ASCO

29 May 2024
3 min read

Regeneron Pharmaceuticals, Inc. released positive outcomes from an ongoing Phase 1/2 clinical study assessing its pioneering costimulatory bispecific antibody, REGN7075 (EGFRxCD28), combined with Libtayo® (cemiplimab) in patients suffering from advanced solid tumors. Findings from the dose-escalation phase demonstrated that this investigational combination elicited anti-tumor responses in patients with microsatellite stable colorectal cancer.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

REGN7075 is pioneering among immunotherapies in demonstrating efficacy in MSS CRC, notably in a patient with hepatic metastases. The findings are set to be presented during an oral session at the American Society of Clinical Oncology 2024 Annual Meeting in Chicago.

"Microsatellite stable colorectal cancer has traditionally shown resistance to immunotherapy," said Neil H. Segal, M.D., Ph.D., a Medical Oncologist and Research Director in the Division of Gastrointestinal Oncology at Memorial Sloan Kettering Cancer Center, and a trial investigator. "Preliminary data for this innovative EGFRxCD28 costimulatory bispecific when combined with Libtayo are promising, indicating anti-tumor activity in a particularly hard-to-treat cancer. This therapeutic regime is among the first immunotherapies to exhibit clinical activity in microsatellite stable colorectal cancer, and we are eager to extend this trial to additional cancer types."

In the dose-escalation phase of the study, patients with metastatic or locally advanced solid tumors – who had no remaining standard treatment options, most of whom also had liver metastases – received a combination therapy of REGN7075 and Libtayo, preceded by a lead-in dose of REGN7075 monotherapy.

"Regeneron is dedicated to developing an innovative oncology portfolio that includes checkpoint inhibitors, CD3 bispecifics, and CD28 costimulatory bispecifics. Over recent years, we have advanced our programs in checkpoint inhibitors and the CD3 category, and we are now observing promising activity with two costimulatory bispecific antibodies," stated Israel Lowy, M.D., Ph.D., Senior Vice President, Translational and Clinical Oncology at Regeneron.

The combination of REGN7075 and Libtayo is in active clinical development, and its safety and efficacy have not yet been fully assessed by any regulatory authority. While the dose-escalation phase for multiple solid tumor types, including non-small cell lung cancer, colorectal cancer, head and neck cancer, and others is progressing, expansion cohorts in several tumor types have also commenced.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of May 29, 2024, there are 3 investigational drugs for the CD28 x EGFR targets, including 4 indications, 3 R&D institutions involved, with related clinical trials reaching 1, and as many as 9773 patents.

Dalmitamig is a bispecific antibody drug targeting CD28 x EGFR, with a focus on treating advanced cancer and advanced malignant solid neoplasms. Its development by Regeneron Pharmaceuticals, Inc. and its current Phase 1/2 status indicate its potential as a promising therapeutic option for patients with these conditions.

图形用户界面, 文本, 网站

描述已自动生成

I-Mab Unveils Promising Phase 1 Results for Ragistomig at ASCO 2024
Latest Hotspot
3 min read
I-Mab Unveils Promising Phase 1 Results for Ragistomig at ASCO 2024
29 May 2024
I-Mab Releases Promising Phase 1 Results for PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024.
Read →
BioAtla to Present Promising Phase 1 Evalstotug Trial Results at 2024 ASCO Conference
Latest Hotspot
3 min read
BioAtla to Present Promising Phase 1 Evalstotug Trial Results at 2024 ASCO Conference
29 May 2024
BioAtla to Showcase Phase 1 Evalstotug Clinical Trial Outcomes Highlighting Clinical Benefits at the 2024 ASCO Annual Conference.
Read →
Sensei Biotherapeutics Shares Encouraging Phase 1 Dose Escalation Study Results for SNS-101
Latest Hotspot
3 min read
Sensei Biotherapeutics Shares Encouraging Phase 1 Dose Escalation Study Results for SNS-101
29 May 2024
Sensei Biotherapeutics, Inc. has announced promising clinical results from the dose-escalation segment of its Phase 1/2 study on SNS-101.
Read →
Coherus Reveals Initial Findings from Phase I Dose-escalation Trial of its CCR8-targeting Antibody, CHS-114
Latest Hotspot
3 min read
Coherus Reveals Initial Findings from Phase I Dose-escalation Trial of its CCR8-targeting Antibody, CHS-114
29 May 2024
Coherus BioSciences, Inc. presented results from the CHS-114 monotherapy dose escalation part of its Phase 1 trial at the ASCO Annual Meeting.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.